Compare Fulford India with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA STRIDES PHARMA SCIENCE FULFORD INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 398.8 16.1 2,473.3% View Chart
P/BV x 6.2 1.0 652.3% View Chart
Dividend Yield % 0.1 0.5 16.6%  

Financials

 FULFORD INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
STRIDES PHARMA SCIENCE
Mar-18
FULFORD INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs9421,147 82.1%   
Low Rs450642 70.1%   
Sales per share (Unadj.) Rs691.4317.2 217.9%  
Earnings per share (Unadj.) Rs11.57.8 146.1%  
Cash flow per share (Unadj.) Rs15.425.1 61.3%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.2 128.5%  
Book value per share (Unadj.) Rs380.0274.3 138.6%  
Shares outstanding (eoy) m3.9089.50 4.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.02.8 35.7%   
Avg P/E ratio x60.7114.0 53.3%  
P/CF ratio (eoy) x45.335.7 126.9%  
Price / Book Value ratio x1.83.3 56.2%  
Dividend payout %17.425.5 68.4%   
Avg Mkt Cap Rs m2,71480,058 3.4%   
No. of employees `0000.42.5 17.7%   
Total wages/salary Rs m5054,341 11.6%   
Avg. sales/employee Rs Th6,073.011,325.8 53.6%   
Avg. wages/employee Rs Th1,137.41,731.4 65.7%   
Avg. net profit/employee Rs Th100.7280.1 35.9%   
INCOME DATA
Net Sales Rs m2,69628,394 9.5%  
Other income Rs m125941 13.3%   
Total revenues Rs m2,82229,334 9.6%   
Gross profit Rs m-463,965 -1.2%  
Depreciation Rs m151,540 1.0%   
Interest Rs m101,962 0.5%   
Profit before tax Rs m541,403 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1097 9.9%   
Profit after tax Rs m45702 6.4%  
Gross profit margin %-1.714.0 -12.3%  
Effective tax rate %17.76.9 255.0%   
Net profit margin %1.72.5 67.0%  
BALANCE SHEET DATA
Current assets Rs m1,73824,836 7.0%   
Current liabilities Rs m54518,993 2.9%   
Net working cap to sales %44.320.6 215.1%  
Current ratio x3.21.3 244.1%  
Inventory Days Days4871 68.3%  
Debtors Days Days4113 3.8%  
Net fixed assets Rs m1234,289 0.0%   
Share capital Rs m39895 4.4%   
"Free" reserves Rs m1,44323,651 6.1%   
Net worth Rs m1,48224,546 6.0%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m2,07765,437 3.2%  
Interest coverage x6.71.7 391.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.4 299.2%   
Return on assets %2.64.1 64.1%  
Return on equity %3.02.9 105.4%  
Return on capital %4.36.9 62.4%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1715,697 0.1%   
Fx outflow Rs m673735 91.5%   
Net fx Rs m-65614,962 -4.4%   
CASH FLOW
From Operations Rs m901,871 4.8%  
From Investments Rs m1055,826 1.8%  
From Financial Activity Rs m-14-10,157 0.1%  
Net Cashflow Rs m181-2,615 -6.9%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 37.8 10.1%  
FIIs % 0.1 8.6 1.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 25.9 81.9%  
Shareholders   4,783 56,241 8.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  VENUS REMEDIES  

Compare FULFORD INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS